T and NK cells: two sides of tumor immunoevasion

Table 1 Ongoing clinical trials with IDO inhibitors ¹

Trial number	Treatment	Tumor	status	Estimated completion	Sponsor/Institution
NCT01219348	peptide²	NSCLC³	recruiting	June 2012	Herlev Hospital, Copenhagen, Denmark
NCT01685255	INCB024360⁴	Ovarian cancer	recruiting	Nov 2015	Incyte Corporation, Wilmington, DE
NCT01543464	peptide²	melanoma	recruiting	Sept 2014	Herlev Hospital, Copenhagen, Denmark
NCT00739609	1-methyl-D-tryptophan⁵	Various solid tumors	terminated	Oct 2012	Vanderbilt University, Nashville, TN and New Link Genetics Corporation, Ames, IA
NCT00567931	1-methyl-D-tryptophan⁵	Various solid tumors	recruiting	undefined	Lee Moffit Cancer Center, Tampa, FL and Virginia Commonwealth University, Richmond, VA.
NCT01604889	INCB024360⁴	melanoma	recruiting	Feb 2015	Various locations, Incyte Corporation, Wilmington, DE
NCT01195311	INCB024360⁴	Various solid tumors	Active, recruiting	Mar 2013	Incyte Corporation, Wilmington, DE

¹ Last searched online (http://www.clinicaltrials.gov) on January 10, 2013. Only trials involving patient treatment were selected. No observational trials are included. Search string: “IDO”.
² Vaccination scheme against an IDO epitope.
³ Non-Small Cell Lung Cancer.
⁴ Small molecule inhibiting IDO enzymatic activity.
⁵ A classical IDO inhibitor.

ISSN: 1479-5876